LONDON, May 28, 2013 /PRNewswire/ – Avillion LLP, which focuses on clinical co-development of therapeutics, today announced the expansion of its leadership team with the appointment of Ramani Varanasi, MSc, MBA, as Chief Business Officer.
Ramani is an accomplished business executive, bringing over 18 years of biotechnology and pharmaceutical industry experience to Avillion. She has a distinguished track record in structuring, negotiating and executing successful strategic alliances, licensing agreements and M&A transactions as well as providing business development, management and strategic leadership to organisations.
Over her career, Ramani has held research and senior level positions in business & corporate development including at Merck, Millennium/Takeda, Momenta Pharmaceuticals, Archemix and RXi Pharmaceuticals.
Lewis Cameron, CEO of Avillion, commented: "We are excited to have Ramani on the Avillion team, where our key focus is the execution of co-development and financing deals with pharma and biotech companies. Her experience and leadership in business and corporate development will support Avillion in its goal of establishing partnerships on late-stage clinical assets."
Ramani holds a BSc and an MSc from McGill University in Microbiology & Immunology and Biochemistry, respectively, and an MBA in General Strategy from Northeastern University.
Avillion LLP is registered in London, UK, and funded by the international venture capital groups Abingworth and Clarus Ventures. The company invests in late stage clinical development projects providing finance and risk sharing to pharma and biotech companies. Avillion has drug development and regulatory expertise to obtain global approvals of a broad range of drugs and biologics.
Tasha Regis-Basin, Avillion LLP Tel: 0207 470 2458 Email